CoChat

Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation

Open access
Seiffge, David J., De Marchis, Gian Marco, Koga, Masatoshi, Paciaroni, Maurizio, Wilson, Duncan, Cappellari, Manuel, Macha, MD, Kosmas, Tsivgoulis, Georgios, Ambler, Gareth, Arihiro, Shoji, Bonati, Leo H., Bonetti, Bruno, Kallmünzer, Bernd, Muir, Keith W., Bovi, Paolo, Gensicke, Henrik, Inoue, Manabu, Schwab, Stefan, Yaghi, Shadi, Brown, Martin M., Lyrer, Philippe, Takagi, Masahito, Acciarrese, Monica, Jager, Hans Rolf, Polymeris, Alexandros A., Toyoda, Kazunori, Venti, Michele, Traenka, Christopher, Yamagami, Hiroshi, Alberti, Andrea, Yoshimura, Sohei, Caso, Valeria, Engelter, Stefan T., Werring, David J., the RAF, RAF‐DOAC, CROMIS‐2, SAMURAI, NOACISP, Erlangen, and Verona registry collaborators · 2020 · Annals of Neurology
Cited by 227

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Objective: It is not known whether patients with atrial fibrillation (AF) with ischemic stroke despite oral anticoagulant therapy are at increased risk for further recurrent strokes or how ongoing secondary prevention should be managed. Methods: We conducted an individual patient data pooled analysis of 7 prospective cohort studies that recruited patients with AF and recent cerebral ischemia. We compared patients taking oral anticoagulants (vitamin K antagonists [VKA] or direct oral anticoagulants [DOAC]) prior to index event (OAC prior) with those without prior oral anticoagulation (OAC naive). We further compared those who changed the type (ie, from VKA or DOAC, vice versa, or DOAC to DOAC) of anticoagulation (OAC changed) with those who continued the same anticoagulation as secondary prevention (OAC unchanged). Time to recurrent acute ischemic stroke (AIS) was analyzed using multivariate competing risk Fine–Gray models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Results: We included 5,413 patients (median age = 78 years [interquartile range (IQR) = 71–84 years]; 5,136 [96.7%] had ischemic stroke as the index event, median National Institutes of Health Stroke Scale on admission = 6 [IQR = 2–12]). The median CHA 2 DS 2‐Vasc score (congestive heart failure, hypertension, age≥ 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65–74 years, sex category) was 5 (IQR = 4–6) and was similar for OAC prior (n = 1,195) and OAC naive (n = 4,119, p = 0.103). During 6,128 patient‐years of follow‐up, 289 patients had AIS (4.7% per year, 95% CI = 4.2–5.3%). OAC prior was associated with an increased risk of AIS (HR = 1.6, 95% CI = 1.2–2.3, p = 0.005). OAC changed (n = 307) was not associated with decreased risk of AIS (HR = 1.2, 95% CI = 0.7–2.1, p = 0.415) compared with OAC unchanged (n = 585). Interpretation: Patients with AF who have an ischemic stroke despite previous oral anticoagulation are at a higher risk for recurrent ischemic stroke despite a CHA 2 DS 2‐Vasc score similar to those without prior oral anticoagulation. Better prevention strategies are needed for this high‐risk patient group. ANN NEUROL 2020;87:677–687

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.25700

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Seiffge, D. J., De Marchis, G. M., Koga, M., Paciaroni, M., Wilson, D., Cappellari, M., Macha, M., Tsivgoulis, G., Ambler, G., Arihiro, S., Bonati, L. H., Bonetti, B., Kallmünzer, B., Muir, K. W., Bovi, P., Gensicke, H., Inoue, M., Schwab, S., Yaghi, S., Brown, M. M., Lyrer, P., Takagi, M., Acciarrese, M., Jager, H. R., Polymeris, A. A., Toyoda, K., Venti, M., Traenka, C., Yamagami, H., Alberti, A., Yoshimura, S., Caso, V., Engelter, S. T., Werring, D. J., & the RAF, R.
Venue
Annals of Neurology
Publisher
Wiley
Published
2020-02-27
Volume
87
Issue
5
Pages
677-687
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W3006079315
Cited by
227
References
7
FWCI
16.34
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.